Jay Vega
Family Medicine · Cut Off, LANPI 1457395659
Payments from drug & device makers
Across 215 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$295
- GSK$212
- Amgen$205
- Lilly USA, LLC$179
- Novo Nordisk$168
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,570100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,077 |
| AstraZeneca | 17 | $295 |
| GSK | 12 | $212 |
| Amgen | 13 | $205 |
| Lilly USA, LLC | 12 | $179 |
| Novo Nordisk | 11 | $168 |
| Pfizer | 12 | $167 |
| Teva Pharmaceuticals USA, Inc. | 9 | $153 |
| Biohaven Pharmaceuticals, Inc. | 7 | $140 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $137 |
| Exact Sciences | 5 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Astellas Pharma US Inc | 6 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Boehringer Ingelheim | 4 | $50 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Alkermes, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Resmed Corp | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Braeburn Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Novartis | 1 | $16 |
| Medtronic | 1 | $15 |
| Merck | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,570 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $137,777 |
| MounjaroTirzepatide | 69 | $90,448 |
| JardianceEmpagliflozin | 75 | $68,653 |
| EliquisApixaban | 72 | $48,579 |
| FarxigaDapagliflozin Propanediol | 55 | $41,398 |
| LinzessLinaclotide | 64 | $40,479 |
| RybelsusSemaglutide | 19 | $33,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,301 |
| JanuviaSitagliptin Phosphate | 34 | $25,286 |
| TrulicityDulaglutide | 13 | $17,279 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $17,141 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $15,601 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 653 | $12,698 |
| MyrbetriqMirabegron | 26 | $11,667 |
| Repatha SyringeEvolocumab | 14 | $8,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $168 | $171,583132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $179 | $107,72782 claims |
| Boehringer IngelheimJardiance | $50 | $68,65375 claims |
| PfizerEliquis | $167 | $48,57972 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $212 | $47,90160 claims |
| AstraZenecaFarxiga | $295 | $41,39855 claims |
| AbbVieLinzess | $1,077 | $40,47964 claims |
| MerckJanuvia | $15 | $25,28634 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $11,66726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Cut Off
- Gary BirdsallCut Off$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.